ERJ Open Research (Aug 2023)

Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis

  • Hongjo Choi,
  • Jeongha Mok,
  • Young Ae Kang,
  • Dawoon Jeong,
  • Hee-Yeon Kang,
  • Hee Jin Kim,
  • Hee-Sun Kim,
  • Doosoo Jeon

DOI
https://doi.org/10.1183/23120541.00135-2023
Journal volume & issue
Vol. 9, no. 4

Abstract

Read online

Background This study evaluated the risk factors of long-term mortality in patients with multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in South Korea who were lost to follow-up (LTFU). Methods This was a retrospective longitudinal follow-up study using an integrated database constructed by data linkage of the three national databases, which included 7226 cases of MDR/RR-TB notified between 2011 and 2017 in South Korea. Post-treatment outcomes of patients who were LTFU were compared with those of patients who achieved treatment success. Results Of the 7226 MDR/RR-TB cases, 730 (10.1%) were LTFU. During a median follow-up period of 4.2 years, 101 (13.8%) of the LTFU patients died: 25 deaths (3.4%) were TB related and 76 (10.4%) were non-TB related. In the LTFU group, the adjusted hazard ratio (aHR) of all-cause mortality (aHR 2.50, 95% CI 1.99–3.15, p55 years, fluoroquinolone resistance, cancer and no retreatment. In the LTFU patients who did not receive retreatment, the risk of non-TB-related mortality (aHR 5.00, 95% CI 1.53–16.37, p=0.008) and consequent all-cause mortality (aHR 2.18, 95% CI 1.08–4.40, p=0.030) was significantly higher than that of patients who received retreatment. Conclusion Non-TB-related mortality was the main cause of death and might be reduced by retreatment in LTFU patients with MDR/RR-TB.